BSE:500660

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

GlaxoSmithKline Pharmaceuticals

Executive Summary

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has GlaxoSmithKline Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 500660 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.6%

500660

7.3%

IN Pharmaceuticals

1.3%

IN Market


1 Year Return

22.6%

500660

52.2%

IN Pharmaceuticals

4.3%

IN Market

Return vs Industry: 500660 underperformed the Indian Pharmaceuticals industry which returned 52.2% over the past year.

Return vs Market: 500660 exceeded the Indian Market which returned 4.3% over the past year.


Shareholder returns

500660IndustryMarket
7 Day1.6%7.3%1.3%
30 Day14.1%5.7%1.8%
90 Day24.1%22.2%13.8%
1 Year25.9%22.6%54.1%52.2%6.3%4.3%
3 Year48.0%39.9%35.4%31.7%4.4%-0.5%
5 Year9.5%0.9%8.4%4.5%46.0%35.1%

Price Volatility Vs. Market

How volatile is GlaxoSmithKline Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

318.04x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500660 (₹1698.95) is trading above our estimate of fair value (₹543.3)

Significantly Below Fair Value: 500660 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500660 is poor value based on its PE Ratio (318x) compared to the IN Pharmaceuticals industry average (22.5x).

PE vs Market: 500660 is poor value based on its PE Ratio (318x) compared to the Indian market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: 500660 is poor value based on its PEG Ratio (9.2x)


Price to Book Ratio

PB vs Industry: 500660 is overvalued based on its PB Ratio (15.8x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

34.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500660's forecast earnings growth (34.5% per year) is above the savings rate (7.2%).

Earnings vs Market: 500660's earnings (34.5% per year) are forecast to grow faster than the Indian market (26.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 500660's revenue (10.5% per year) is forecast to grow slower than the Indian market (11.7% per year).

High Growth Revenue: 500660's revenue (10.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (31.1%)


Next Steps

Past Performance

How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?

-8.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 500660 has a large one-off loss of ₹3.4B impacting its June 30 2020 financial results.

Growing Profit Margin: 500660's current net profit margins (2.9%) are lower than last year (15.1%).


Past Earnings Growth Analysis

Earnings Trend: 500660's earnings have declined by 8.9% per year over the past 5 years.

Accelerating Growth: 500660's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 500660 had negative earnings growth (-81.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.7%).


Return on Equity

High ROE: 500660's Return on Equity (5%) is considered low.


Next Steps

Financial Health

How is GlaxoSmithKline Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 500660's short term assets (₹17.7B) exceed its short term liabilities (₹10.2B).

Long Term Liabilities: 500660's short term assets (₹17.7B) exceed its long term liabilities (₹2.9B).


Debt to Equity History and Analysis

Debt Level: 500660's debt to equity ratio (0.01%) is considered satisfactory.

Reducing Debt: 500660's debt to equity ratio has reduced from 0.1% to 0.01% over the past 5 years.

Debt Coverage: 500660's debt is well covered by operating cash flow (277118.5%).

Interest Coverage: 500660 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.18%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 500660's dividend (1.18%) is higher than the bottom 25% of dividend payers in the Indian market (0.55%).

High Dividend: 500660's dividend (1.18%) is low compared to the top 25% of dividend payers in the Indian market (2.23%).


Stability and Growth of Payments

Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500660's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (374.4%), 500660's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Sridhar Venkatesh

0.42

Tenure

Mr. Sridhar Venkatesh serves as Managing Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkline Pharmaceu ...


Leadership Team

NamePositionTenureCompensationOwnership
Puja Thakur
South Asia Finance Director2.67yrs₹43.38mno data
Raju Krishnaswamy
Executive Director of Technical9.08yrs₹28.94mno data
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹13.24mno data
Meenakshi Priyam
Executive Vice President of Human Resources2.83yrs₹41.34mno data
Anil Iyer
Chief Commercial Officer of Pharmaceuticals3yrs₹45.42mno data
Sridhar Venkatesh
Managing Director0.42yrno datano data
S. Balasubramanian
Vice President of Ethics & Compliance1.92yrsno datano data
S. Zota
Executive Vice President of Legal0.50yrno datano data
Ransom D'Souza
Vice President of Communications & Government Affairs3.42yrsno datano data
Sumer Dheri
Executive Vice President of Vaccines3.42yrsno datano data
Sukanya Choudhury
Executive Vice-President of Regulatory Affairsno datano datano data
Deepshikha Jakate
Regional Quality Head South Asia & Vice President of Quality2.58yrsno datano data

2.8yrs

Average Tenure

Experienced Management: 500660's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Puja Thakur
South Asia Finance Director2.67yrs₹43.38mno data
Raju Krishnaswamy
Executive Director of Technical9.08yrs₹28.94mno data
Sridhar Venkatesh
Managing Director0.42yrno datano data
Renu Karnad
Independent Chairperson1.42yrs₹2.90m0.00035%
₹ 1.0m
Nihal Vijaya Devadas Kaviratne
Non-Executive Independent Director15.17yrs₹2.25mno data
Damodarannair Sundaram
Non-Executive Independent Director11.17yrs₹2.10mno data
Subesh Williams
Non Executive Director3.42yrsno datano data
Pradeep Bhide
Non-Executive Independent Director9.92yrs₹2.20mno data
Anami Roy
Non-Executive Independent Director8.83yrs₹1.80mno data
Sunita Maheshwari
Additional Independent Director0.33yrno datano data

6.1yrs

Average Tenure

67.5yo

Average Age

Experienced Board: 500660's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

GlaxoSmithKline Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Pharmaceuticals Limited
  • Ticker: 500660
  • Exchange: BSE
  • Founded: 1924
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹287.812b
  • Shares outstanding: 169.41m
  • Website: https://www.india-pharma.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Pharmaceuticals Limited
  • GSK House
  • Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500660BSE (Mumbai Stock Exchange)YesEquity SharesININRJun 1996
GLAXONSEI (National Stock Exchange of India)YesEquity SharesININRJun 1996

Biography

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescript ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 19:14
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.